Why BCMA Alone Is No Longer Enough

Multiple myeloma remains an incurable plasma cell malignancy, and while BCMA (B-cell maturation antigen; TNFRSF17) has served as the anchor target for the first generation of engineered immunotherapy, antigen escape and relapsed/refractory disease continue to create significant unmet need. BCMA is a non-glycosylated type III transmembrane protein preferentially expressed on differentiated plasma cells and universally detected on myeloma cells; its ligands APRIL and BAFF activate NF-κB, Elk-1, c-JUN N-terminal kinase, and p38 MAPK pathways to promote plasma cell survival and proliferation.

A critical limitation of BCMA-directed monotherapy is the emergence of soluble BCMA (sBCMA), shed from the membrane surface by gamma-secretase cleavage. This soluble form acts as a decoy, potentially reducing the efficacy of BCMA-directed agents and representing a recognized therapeutic challenge across all BCMA-targeting modalities. The patent landscape analysed here—spanning bispecific antibodies, CAR-T constructs, trispecific molecules, and NK-cell engagers—reflects the field’s response to this fundamental biological constraint.

The retrieved patent dataset also documents a vaccine-based modality from Dana-Farber Cancer Institute, where BCMA and TACI immunogenic peptides are encapsulated in PLGA nanoparticles to induce cytotoxic T lymphocyte (CTL) responses. PLGA-encapsulated BCMA peptides demonstrated the highest anti-myeloma cytotoxic activity in this dataset, with CD107a degranulation of 31.7% for PLGA/peptide CTLs versus 15.0% for peptide alone against primary CD138+ myeloma cells—illustrating that even within BCMA-directed approaches, novel delivery formats continue to emerge alongside the dominant antibody and cellular platforms.

GPRC5D and FcRH5: The Leading Post-BCMA Plasma Cell Targets

GPRC5D and FcRH5 have emerged as the two most clinically relevant alternatives to BCMA for targeting malignant plasma cells, each offering a distinct biological rationale and a different competitive IP landscape. GPRC5D (G protein-coupled receptor class C group 5 member D; UniProt Q9NZD1) is a 39 kDa, seven-transmembrane GPCR in the RAIG (retinoic acid-inducible gene-1) family. Records from Memorial Sloan Kettering Cancer Center and Juno Therapeutics confirm that GPRC5D is highly expressed on myeloma cells and malignant plasma cells while demonstrating low expression across most normal tissues—the selectivity profile that makes it therapeutically attractive.

“GPRC5D and BCMA expression are described as largely independent of each other, providing the primary mechanistic rationale for dual-targeting strategies designed to prevent antigen escape.”

The independence of GPRC5D and BCMA expression is the single most important biological feature driving the dual-targeting strategies documented across this dataset. When myeloma cells downregulate BCMA under therapeutic pressure, GPRC5D expression is not co-ordinately reduced—meaning GPRC5D-directed agents retain activity against BCMA-escape variants. This independence is explicitly cited as the mechanistic justification in records from at least four distinct assignees: Janssen, Memorial Sloan Kettering Cancer Center, Juno Therapeutics (now part of Bristol Myers Squibb), and multiple Chinese biotech entities.

FcRH5 (Fc receptor-like 5; FcRL5/FCRL5) occupies a more concentrated IP space. As an Fc receptor-like protein expressed on plasma cells, FcRH5 functions as the tumour-directed arm of bispecific antibodies pairing it with CD3 for T cell redirection. Genentech (a member of the Roche Group) is the sole assignee in the retrieved dataset for FcRH5×CD3 bispecific antibody dosing and diagnostic strategy in myeloma. A 2025 CN patent explicitly describes patient monitoring methods—measuring T cell proliferation markers post-dosing, comparing to a reference level, and making continuation-of-therapy decisions—consistent with a clinical or late-stage investigational context. This Genentech dominance in FcRH5 IP means non-Roche actors seeking FcRH5-directed programmes face significant freedom-to-operate constraints at the antibody format level, though novel CAR constructs and combination regimens may offer alternative entry points.

Six Therapeutic Modalities Competing for the Myeloma Pipeline

The retrieved patent dataset reveals six distinct therapeutic modalities targeting plasma cells in myeloma, ranging from mature bispecific T-cell engager formats to emerging NK-cell engagers and peptide vaccines. Each modality carries a different IP density, clinical maturity signal, and antigen-escape mitigation profile.

1. BCMA×CD3 Bispecific T-Cell Engagers

The largest cluster of retrieved patent records covers bispecific antibodies co-engaging BCMA on plasma cells and CD3ε on T cells. These molecules redirect T cell cytotoxicity in a BCMA-dependent manner, inducing concentration-dependent lysis of patient bone marrow myeloma plasma cells while sparing T cells, B cells, and NK cells. Retrieved records confirm that control T-cell bispecifics (TCBs) binding only CD3 do not induce myeloma plasma cell death, confirming the tumour-antigen-dependent mechanism. Multiple formats are covered: IgG-based TCBs, Fabs-in-Tandem immunoglobulins (FIT-Igs), BiTE-like formats, and bispecific ankyrin repeat molecules. Regeneron Pharmaceuticals holds a concentrated portfolio in this space, with records across IL, CA, US, and SG jurisdictions also describing combination with cemiplimab (REGN2810), an anti-PD-1 antibody, to achieve synergistic anti-tumour effects in BCMA-expressing tumours—consistent with the known immunosuppressive bone marrow microenvironment in myeloma.

2. GPRC5D×CD3 Bispecific Antibodies

Retrieved records from Janssen Biotech specifically describe GPRC5D×CD3 bispecific antibodies for treatment of relapsed and/or refractory myeloma, operating by the same T cell redirection mechanism as BCMA×CD3 agents but engaging a structurally and expressionally distinct plasma cell surface target. These molecules are covered in the context of both monotherapy and combination with anti-BCMA CAR-T cell therapy. Retrieved records specify clinical response outcomes including CR and sCR per IMWG criteria, and include both newly diagnosed transplant-ineligible patients and relapsed/refractory patients who have received at least one prior line of therapy—signals of clinical-stage or near-clinical development.

3. FcRH5×CD3 Bispecific Antibodies

Genentech’s retrieved records describe a dosing method for anti-FcRH5×anti-CD3 bispecific antibody in cancer including myeloma, paired with a biomarker strategy: monitoring T cell proliferation markers post-dosing to identify responsive patients and guide treatment continuation. This patient stratification approach—measuring T cell proliferation markers, comparing to a reference level, and deciding whether to continue therapy—represents a more translational signal relative to the preclinical GPRC5D data also present in this dataset, and is consistent with late-stage investigational or clinical use.

4. CAR-T Cell Therapies: BCMA-Directed and Dual-Targeting

Multiple assignees have filed patents on BCMA-directed CAR-T cells, with retrieved records covering anti-BCMA CARs from Pfizer, 2seventy bio, Juno Therapeutics, Nkarta, Nanjing Legend Biotech, Bar Ilan University, and others. Key design features include single-domain antibodies (nanobodies) as antigen-binding domains, multivalent or dual-epitope CARs to reduce tumour escape, third-generation CARs with modified co-stimulatory domains (4-1BB, ICOS), and co-expression of additional targets. Dual-targeting CARs co-recognising BCMA and GPRC5D are described by Juno Therapeutics (now part of Bristol Myers Squibb), explicitly designed to prevent antigen escape through independent BCMA/GPRC5D loss. Dual BCMA/FcRH5-targeting CARs using nanobodies are covered by Bonner Tai (Shandong) Biopharmaceutical Technology Group Co., Ltd., employing humanised nanobody constructs against both targets delivered via lentiviral CAR vectors.

5. NK-Cell Engaging Multispecific Constructs

Affimed GmbH describes multispecific antigen-binding proteins designed to engage NK cells via CD16A (FcγRIIIA), incorporating at least two CD16A-binding moieties fused to BCMA-targeting moieties. This NK-cell redirection approach represents an alternative effector cell strategy distinct from T cell-engaging bispecifics. The format uses tandem scFv chains with light chain variable regions at the N-terminus. Retrieved records suggest combination with checkpoint modulators including anti-LAG3 and anti-PD-1 antibodies, signalling expansion of effector cell recruitment strategies beyond T cells.

6. BCMA Peptide Vaccine (CTL-Based)

Records from Dana-Farber Cancer Institute describe BCMA and TACI immunogenic peptides for CTL-based vaccination, with PLGA-encapsulated BCMA peptides demonstrating the highest anti-myeloma cytotoxic activity in this dataset: CD107a degranulation of 31.7% for PLGA/peptide CTLs versus 15.0% for peptide alone against primary CD138+ myeloma cells. This non-antibody, CTL-induction modality could eventually serve as a maintenance or combination therapy strategy, representing a distinct mechanism from all antibody and cellular platforms described above.

Trispecific Antibodies and the Antigen-Escape Endgame

Trispecific antibodies co-engaging BCMA, GPRC5D, and CD3 represent the most architecturally ambitious molecular strategy in the retrieved dataset, designed to simultaneously prevent antigen escape through either BCMA or GPRC5D loss while redirecting T cells against plasma cells. Janssen Pharmaceutica N.V. has filed patents in IL (2023) and JP (2024) jurisdictions on such molecules, with related polynucleotides, expression vectors, and detectably labelled versions also covered—indicating active international prosecution of this IP across multiple jurisdictions.

The combination of anti-BCMA CAR-T with GPRC5D×CD3 bispecific antibody—with or without BCMA×CD3 bispecific antibody—is intended to simultaneously overcome antigen heterogeneity and CAR-T cell insufficiency. The inclusion of both newly diagnosed transplant-ineligible patients and relapsed/refractory patients in Janssen’s patent records signals that this triplet approach is not restricted to late-line salvage but is being evaluated across the myeloma treatment continuum. This is consistent with broader trends in haematological oncology, where according to WIPO data on immunotherapy patent filings, combination immuno-oncology strategies have become the dominant patent filing category over the past five years.

Beyond the triplet regimen, dual-targeting CARs offer an alternative cellular approach to the same antigen-escape problem. Juno Therapeutics’ GPRC5D+BCMA dual-CAR and Bonner Tai’s BCMA/FcRH5 nanobody-CAR represent independent BCMA-escape mitigation strategies using cellular rather than antibody platforms. The University of Pennsylvania also references FCRL2 and FCRL5 as targets in combination with BCMA CAR-T therapy to address antigen escape, further extending the combinatorial target space beyond the three antigens covered most prominently in this dataset. As noted by NIH-funded research on CAR-T cell persistence, multi-antigen targeting strategies are increasingly recognised as necessary to achieve durable responses in heavily pre-treated myeloma patients.

The Regeneron BCMA×CD3 bsAb plus cemiplimab (REGN2810, an anti-PD-1 antibody) combination adds a checkpoint inhibitor dimension to the bispecific antibody strategy, consistent with the known immunosuppressive bone marrow microenvironment in myeloma. Affimed’s NK-cell engaging CD16A×BCMA multispecific format, with combination checkpoint modulators (anti-LAG3, anti-PD-1) suggested in retrieved records, similarly signals expansion of effector cell recruitment strategies beyond T cells. Collectively, these combination signals suggest that the field is converging on multi-modal immune engagement as the standard architecture for next-generation myeloma regimens, a direction also tracked by EMA in its horizon-scanning activities for advanced therapy medicinal products.

Who Owns the IP: Assignee Landscape and Strategic Implications

Innovation in the myeloma bispecific and CAR-T space is overwhelmingly patent-driven, with minimal academic paper contribution on the myeloma-specific targets in the retrieved dataset. The major assignee clusters reveal a highly concentrated competitive landscape with significant implications for freedom-to-operate analysis and pipeline strategy.

Janssen (Johnson & Johnson) holds the most comprehensive multi-modal myeloma IP portfolio in this dataset, spanning GPRC5D×CD3 bispecific antibodies, trispecific BCMA+GPRC5D+CD3 antibodies, and combination CAR-T plus bispecific regimens. IP activity spans WO, US, IL, and JP jurisdictions—a pattern consistent with a deliberate freedom-to-operate and patent-fencing strategy around non-BCMA plasma cell targets. New entrants should anticipate a dense IP landscape around GPRC5D binding domains and CAR constructs, with coverage by at least four distinct assignees: Janssen, Memorial Sloan Kettering Cancer Center, Juno Therapeutics/BMS, and Chinese biotech entities.

Genentech (Roche Group) is the sole assignee in this dataset for FcRH5×CD3 bispecific antibody dosing and diagnostic strategy in myeloma. This concentration means non-Roche actors seeking FcRH5-directed programmes face significant freedom-to-operate constraints at the antibody format level. Novel CAR constructs (as filed by Bonner Tai) and combination regimens may offer alternative entry points, but these remain earlier-stage relative to Genentech’s clinical signals. The strategic implications for portfolio planning in this space are significant and merit analysis using tools such as those available through PatSnap Analytics.

Chinese biotech entities—including Nanjing Legend Biotech, Bonner Tai (Shandong) Biopharmaceutical Technology Group, and Shanghai EpimAb Biotherapeutics—are active across BCMA CAR-T, dual BCMA/FcRH5 nanobody-CAR, and BCMA×CD3 bispecific antibody modalities, primarily in CN and IL jurisdictions. Nanjing Legend Biotech’s patent records reference clinical data including 94% of patients showing clinical remission within 2 months of CAR-T treatment, and patients achieving sCR remaining MRD-negative over one year post-treatment—among the strongest translational signals in the dataset.

“Antigen escape mitigation is the dominant engineering rationale across retrieved results: both dual-antigen CARs and trispecific antibodies are explicitly framed as solutions to BCMA downregulation observed in relapsed disease.”

No retrieved records in this dataset explicitly disclose completed Phase III trial results, regulatory submissions, or approved label language for GPRC5D or FcRH5-directed agents—consistent with the patent-centric nature of this dataset. However, the embedding of IMWG clinical response criteria (PR, VGPR, CR, sCR) and MRD-negativity thresholds at 10⁻⁵ in active patent filings, combined with the inclusion of defined patient populations (newly diagnosed transplant-ineligible and relapsed/refractory with at least one prior line of therapy), provides strong signals of clinical-stage or near-clinical development for the leading Janssen programmes. Developers designing clinical programmes should incorporate sequential or concurrent immune effector cell and bispecific engager regimens, and should build biomarker strategies around independent GPRC5D versus BCMA expression profiling for patient selection and pharmacodynamic monitoring—guidance consistent with standards outlined by EMA for advanced therapy medicinal products in haematological malignancies.